News and reports from Europe.

The European Awards Program Announces Release of Video Interview with Head of Marketing Mr. Ergin Erdemir and Commercial Director Mr. Marcos Tigsilema, ATFX UK

The European Awards Program Announces Release of Video Interview with Mr. Daniel Carino, Managing Director & Founder of Oenofuture

The European Announces Release of Video Interview with Mr. Steve Durbin, Managing Director of the Information Security Forum

Soins dentaires en Hongrie - Economisez jusqu'à 70% sur les soins dentaires à Budapest

Les patients en tourisme dentaire peuvent économiser jusqu'à 70% sur les coûts de traitement dentaire en Hongrie par rapport aux pays d'Europe occidentale.

The Birmingham MBA, University of Birmingham

At Birmingham Business School we deliver world-class research and teaching that provides the insight, ambition and skills to shape advanced and sustainable business strategies. The School’s vision is to promote curiosity and thought leadership for responsible business.

Dickkopf-related protein 3 (DKK3) predicts AKI

Acute kidney injury (AKI) is a common complication after cardiac surgery. The severity fluctuates from subclinical AKI, an increase in biochemical markers of kidney injury, to severe AKI requiring renal replacement therapy with dialysis.

Nephrology and Public Policy Committee (NPPC) aims to intensify research activity

Epidemiological and clinical research and public policy in Europe are generally considered to be comprehensive and successful – and the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) is playing a key role in the field of nephrology research.

Indigestion remedy significantly slows kidney function decline and improves survival in late-stage CKD

As chronic kidney disease (CKD) progresses, the kidneys become less able to maintain a healthy balance of acids in the body, a condition known as metabolic acidosis.

Maintaining work during the final 6 months prior to haemodialysis was associated with a better survival

 26% of patients had been employed 6 months prior to dialysis initiation – but this dropped to 15% when dialysis treatment was initiated.

Linagliptin improved albuminuria but had no effect on eGFR and CV risk in patients with diabetes

In the CARMELINA trial nearly 10% of all patients with diabetes had nephrotic-range proteinuria at baseline. This was associated with a high incidence of cardiovascular/kidney disease but this secondary disease burden could not be lowered by linagliptin.


Subscribe to RSS - Europe